In its upcoming report, McKesson (MCK) is predicted by Wall Street analysts to post quarterly earnings of $7.05 per share, reflecting an increase of 2.2% compared to the same period last year. Revenues are forecasted to be $77.48 billion, representing a year-over-year increase of 9.9%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Bef ...

The market expects McKesson (MCK) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 7, 2024, might help the stock move higher if these key numbers are ...

Core Viewpoint - McKesson (MCK) is identified as a strong value stock with a Zacks Rank of 2 (Buy) and an A grade for Value, indicating its potential for investment based on valuation metrics [2][3]. Valuation Metrics - MCK has a P/E ratio of 15.98, which is lower than the industry average of 18.58, suggesting it may be undervalued [2]. - The stock's Forward P/E has fluctuated between 12.75 and 16.26 over the past 52 weeks, with a median of 14.82 [2]. - MCK's PEG ratio stands at 1.53, compared to the industry average of 1.73, indicating a favorable growth outlook relative to its valuation [2]. - The PEG ratio has ranged from 1.23 to 1.55 in the past year, with a median of 1.39 [2]. Cash Flow Metrics - MCK's P/CF ratio is 15.63, significantly lower than the industry average of 20.18, which points to its attractive cash flow valuation [3]. - The P/CF ratio has varied between 11.52 and 15.88 over the last 52 weeks, with a median of 13.25 [3]. Overall Assessment - The combination of MCK's valuation metrics and strong earnings outlook suggests that the stock is likely undervalued, making it an impressive value stock at present [3].

Company Overview - McKesson Corporation (MCK) plans to sell Rexall Pharmacy Group, a Canadian drugstore chain acquired for approximately $2.2 billion seven years ago [1] - The acquisition of Rexall in 2016 was aimed at strengthening McKesson's position in Canada's pharmaceutical supply chain [1] Price Performance - Over the past six months, McKesson's shares have increased by 19.9%, contrasting with a 2.4% decline in the industry and a 3.9% rise in the S&P 500 [2] Sale Process - McKesson has been in discussions with potential buyers for Rexall throughout the summer, currently in the second round of offers without a set deadline for submissions [4] - Rexall operates 400 pharmacies in Canada and employs around 8,000 people; however, the pharmaceutical distribution division may not be included in the sale [4] Industry Context - Pharmaceutical dealmaking in Canada rose to $6.8 billion in 2023 from $1.8 billion in 2022, although it decreased from $7.5 billion in 2021 [4] - In 2021, McKesson divested its European businesses to Phoenix Group, a German drug distributor [4] Notable Developments - In December 2023, McKesson announced the availability of an FDA-approved drug for PNH treatment, which is expected to enhance its position in the global PNH treatment market and boost its Specialty Pharmacy Solutions business [5] Zacks Rank & Other Stocks - McKesson currently holds a Zacks Rank of 2 (Buy) [6] - Other top-ranked stocks in the medical sector include Integer Holdings Corporation, Acadia Healthcare, and Universal Health Services, all carrying a Zacks Rank of 2 [6]

McKessonCorporation (MCK) is well-poised for growth, backed by strategic collaborations and strength in the Distribution Solutions segment. However, the company’s opioid-related litigation expenses are a potential threat.Shares of this currently Zacks Rank #2 (Buy) company have risen 27.4% in the past year compared with the industry’s 9% growth. The S&P 500 Index has increased 20.6% in the same time frame.McKesson is a healthcare services and information technology company with a market capitalization of $6 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside ...

Shares of McKesson Corporation (MCK) scaled a new 52-week high of $485.22 on Jan 3, 2024, before closing the session slightly lower at $480.34.Over the past year, this Zacks Rank #3 (Hold) stock has gained 28.4% compared with 11.7% growth of the industry and a 24.4% rise of the S&P 500 Composite.Over the past five years, the company registered earnings growth of 15.4% compared with the industry’s 9.1% rise. The company’s long-term expected growth rate of 10.5% compares with the industry’s growth projection ...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. McKesson management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024. The live webcast for each event will be available on McKesson’s Inves ...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.McKesson management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.The live webcast for each event will be available on McKesson’s Investor ...

McKesson Corporation (NYSE:MCK) Q2 2024 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Rachel Rodriguez - Vice President of Investor Relations Brian Tyler - Chief Executive Officer Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Eric Percher - Nephron Research Lisa Gill - JPMorgan Charles Rhyee - Cowen & Company Brian Tanquilut - Jefferies Eric Coldwell - Baird Kevin Caliendo - UBS Daniel Grosslight - Citi Research Allen Lutz - Ba ...